keyword
MENU ▼
Read by QxMD icon Read
search

american society of clinical oncology

keyword
https://www.readbyqxmd.com/read/29036041/highlights-in-lymphoma-from-the-2017-american-society-of-clinical-oncology-annual-meeting-and-the-14th-international-conference-on-malignant-lymphoma
#1
(no author information available yet)
No abstract text is available yet for this article.
September 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29035643/role-of-bone-modifying-agents-in-metastatic-breast-cancer-an-american-society-of-clinical-oncology-cancer-care-ontario-focused-guideline-update
#2
Catherine Van Poznak, Mark R Somerfield, William E Barlow, J Sybil Biermann, Linda D Bosserman, Mark J Clemons, Sukhbinder K Dhesy-Thind, Melissa S Dillmon, Andrea Eisen, Elizabeth S Frank, Reshma Jagsi, Rachel Jimenez, Richard L Theriault, Theodore A Vandenberg, Gary C Yee, Beverly Moy
Purpose To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain. Methods A joint ASCO-CCO Update Committee conducted targeted systematic literature reviews to identify relevant studies. Results The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one systematic review and meta-analysis of studies of de-escalation of BMAs, and two randomized trials of BMAs in control of pain secondary to bone metastases...
October 16, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29035617/role-of-bone-modifying-agents-in-metastatic-breast-cancer-an-american-society-of-clinical-oncology-cancer-care-ontario-focused-guideline-update-summary
#3
Catherine Van Poznak, Mark R Somerfield, Beverly Moy
No abstract text is available yet for this article.
October 16, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29025982/appropriate-use-criteria-for-somatostatin-receptor-pet-imaging-in-neuroendocrine-tumors
#4
Thomas A Hope, Emily Bergsland, Murat Fani Bozkurt, Michael M Graham, Anthony P Heaney, Ken Herrmann, James R Howe, Matthew H Kulke, Pamela L Kunz, Josh Mailman, Lawrence May, David C Metz, Corina Millo, Sue O'Dorisio, Diane L Reidy-Lagunes, Michael C Soulen, Jonathan R Strosberg
Somatostatin receptor positron emission tomography (SSTR-PET) is an imaging modality for patients with neuroendocrine tumors (NETs) that has demonstrated a significant improvement over conventional imaging (CI). SSTR-PET should replace In-111 pentetreotide scintigraphy (OctreoScan) in all indications in which SSTR scintigraphy is currently being used. These appropriate use criteria (AUC) are intended to aid referring medical practitioners in the appropriate use of SSTR-PET for imaging of patients with NETs, and the indications were evaluated in well-differentiated NETs...
October 12, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29025266/the-abcs-of-immunotherapy-for-adult-patients-with-b-cell-acute-lymphoblastic-leukemia
#5
Troy Z Horvat, Amanda N Seddon, Adebayo Ogunniyi, Amber C King, Larry W Buie, Ryan J Daley
OBJECTIVE: To review the pharmacology, efficacy, and safety of Food and Drug Administration approved and promising immunotherapy agents used in the treatment of acute lymphoblastic leukemia (ALL). DATA SOURCES: A literature search was performed of PubMed and MEDLINE databases (1950 to July 2017) and of abstracts from the American Society of Hematology and the American Society of Clinical Oncology. Searches were performed utilizing the following key terms: rituximab, blinatumomab, inotuzumab, ofatumumab, obinutuzumab, Blincyto, Rituxan, Gazyva, Arzerra, CAR T-cell, and chimeric antigen receptor (CAR)...
October 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28975009/value-frameworks-in-oncology-comparative-analysis-and-implications-to-the-pharmaceutical-industry
#6
REVIEW
Mark Slomiany, Priya Madhavan, Michael Kuehn, Sasha Richardson
BACKGROUND: As the cost of oncology care continues to rise, composite value models that variably capture the diverse concerns of patients, physicians, payers, policymakers, and the pharmaceutical industry have begun to take shape. OBJECTIVES: To review the capabilities and limitations of 5 of the most notable value frameworks in oncology that have emerged in recent years and to compare their relative value and application among the intended stakeholders. METHODS: We compared the methodology of the American Society of Clinical Oncology (ASCO) Value Framework (version 2...
July 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28973709/distinguishing-depressive-symptoms-from-similar-cancer-related-somatic-symptoms-implications-for-assessment-and-management-of-major-depression-after-breast-cancer
#7
REVIEW
Lora M A Thompson, Margarita Bobonis Babilonia
Prevalence rates of major depressive disorder (MDD) following breast cancer diagnosis are estimated to be ~5% to >20%, and these rates range from slightly below to somewhat above the expected prevalence rate for MDD in the general population of women in the United States. Women with a history of MDD are at increased risk for recurrence of MDD after breast cancer and need to be monitored closely. To properly diagnose and treat MDD, healthcare providers must be able to recognize depressive symptoms and distinguish them from similar somatic symptoms that are associated with breast cancer and breast cancer treatment...
October 2017: Southern Medical Journal
https://www.readbyqxmd.com/read/28970856/comparison-of-core-needle-biopsy-and-surgical-specimens-in-determining-intrinsic-biological-subtypes-of-breast-cancer-with-immunohistochemistry
#8
Kiho You, Sungmin Park, Jai Min Ryu, Isaac Kim, Se Kyung Lee, Jonghan Yu, Seok Won Kim, Seok Jin Nam, Jeong Eon Lee
PURPOSE: We evaluated the concordance between core needle biopsy (CNB) and surgical specimens on examining intrinsic biological subtypes and receptor status, and determined the accuracy of CNB as a basic diagnostic method. METHODS: We analyzed breast cancer patients with paired CNB and surgical specimen samples during 2014. We used monoclonal antibodies for nuclear staining, and estrogen receptor (ER) and progesterone receptor (PR) status evaluation. A positive test was defined as staining greater than or equal to 1% of tumor cells...
September 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28970685/therapeutic-leukocyte-reduction-for-acute-and-chronic-myeloid-leukemias-a-4-year-experience-from-an-oncology-center-in-india
#9
Anita A Tendulkar, Puneet A Jain, Abhaykumar Gupta, Nidhi Sharma, Anisha Navkudkar, Vijaya Patle
INTRODUCTION: Hyperleukocytosis (HL) and leukostasis seen in myeloid leukemias are a medical emergency. We present a case series of ten such patients in a 4-year period. Sixteen therapeutic leukocyte reduction (TLR) were done in ten cases along with other supportive measures. The American Society for Apheresis supports the routine implementation of TLR in cases of HL secondary to myeloid leukemias with signs of leukostasis. MATERIALS AND METHODS: The procedures were performed on the intermittent flow cell separator after discussion with the treating physician about patient's condition...
July 2017: Asian Journal of Transfusion Science
https://www.readbyqxmd.com/read/28968173/modernizing-clinical-trial-eligibility-criteria-recommendations-of-the-american-society-of-clinical-oncology-friends-of-cancer-research-hiv-working-group
#10
Thomas S Uldrick, Gwynn Ison, Michelle A Rudek, Ariela Noy, Karl Schwartz, Suanna Bruinooge, Caroline Schenkel, Barry Miller, Kieron Dunleavy, Judy Wang, Jerome Zeldis, Richard F Little
Purpose People with HIV are living longer as a result of effective antiretroviral therapy. Cancer has become a leading cause of morbidity and mortality in this patient population. However, studies of novel cancer therapeutics have historically excluded patients with HIV. Critical review of eligibility criteria related to HIV is required to accelerate development of and access to effective therapeutics for HIV-infected patients with cancer and make studies more generalizable to this patient population. Methods From January through April 2016, the HIV Working Group conducted a series of teleconferences; a review of 46 New Drug Applications from registration studies of unique agents studied in adults with cancer that led to the initial US Food and Drug Administration approval of that agent from 2011 to 2015; and a review of HIV-related eligibility criteria from National Cancer Institute-sponsored studies...
October 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28968172/modernizing-clinical-trial-eligibility-criteria-recommendations-of-the-american-society-of-clinical-oncology-friends-of-cancer-research-organ-dysfunction-prior-or-concurrent-malignancy-and-comorbidities-working-group
#11
Stuart M Lichtman, R Donald Harvey, Marie-Anne Damiette Smit, Atiqur Rahman, Michael A Thompson, Nancy Roach, Caroline Schenkel, Suanna S Bruinooge, Patricia Cortazar, Dana Walker, Louis Fehrenbacher
Purpose Patients with organ dysfunction, prior or concurrent malignancies, and comorbidities are often excluded from clinical trials. Excluding patients on the basis of these factors results in clinical trial participants who are healthier and younger than the overall population of patients with cancer. Methods ASCO and Friends of Cancer Research established a multidisciplinary working group that included experts in trial design and conduct to examine how eligibility criteria could be more inclusive. The group analyzed current eligibility criteria; conducted original data analysis; considered safety concerns, potential benefits, research, and potential hurdles of this approach through discussion; and reached consensus on recommendations regarding updated eligibility criteria that prioritize inclusiveness without compromising patient safety...
October 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28968170/broadening-eligibility-criteria-to-make-clinical-trials-more-representative-american-society-of-clinical-oncology-and-friends-of-cancer-research-joint-research-statement
#12
Edward S Kim, Suanna S Bruinooge, Samantha Roberts, Gwynn Ison, Nancy U Lin, Lia Gore, Thomas S Uldrick, Stuart M Lichtman, Nancy Roach, Julia A Beaver, Rajeshwari Sridhara, Paul J Hesketh, Andrea M Denicoff, Elizabeth Garrett-Mayer, Eric Rubin, Pratik Multani, Tatiana M Prowell, Caroline Schenkel, Marina Kozak, Jeff Allen, Ellen Sigal, Richard L Schilsky
Purpose The primary purposes of eligibility criteria are to protect the safety of trial participants and define the trial population. Excessive or overly restrictive eligibility criteria can slow trial accrual, jeopardize the generalizability of results, and limit understanding of the intervention's benefit-risk profile. Methods ASCO, Friends of Cancer Research, and the US Food and Drug Administration examined specific eligibility criteria (ie, brain metastases, minimum age, HIV infection, and organ dysfunction and prior and concurrent malignancies) to determine whether to modify definitions to extend trials to a broader population...
October 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28968169/modernizing-clinical-trial-eligibility-recommendations-of-the-american-society-of-clinical-oncology-friends-of-cancer-research-minimum-age-working-group
#13
Lia Gore, S Percy Ivy, Frank M Balis, Eric Rubin, Katherine Thornton, Martha Donoghue, Samantha Roberts, Suanna Bruinooge, Jennifer Ersek, Nancy Goodman, Caroline Schenkel, Gregory Reaman
Purpose Children have historically been excluded from first-in-human studies of promising new cancer drugs and later phase adult clinical trials. Delays in evaluation may result in off-label use without dosing information as the only access to new drugs. A multistakeholder workshop was convened in May 2016 by ASCO and Friends of Cancer Research to identify opportunities for when it would be scientifically appropriate to expand trial eligibility to include children younger than age 18 years in first-in-human and other adult cancer clinical trials...
October 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28968165/modernizing-clinical-trial-eligibility-criteria-recommendations-of-the-american-society-of-clinical-oncology-friends-of-cancer-research-brain-metastases-working-group
#14
Nancy U Lin, Tatiana Prowell, Antoinette R Tan, Marina Kozak, Oliver Rosen, Laleh Amiri-Kordestani, Julia White, Joohee Sul, Louise Perkins, Katherine Beal, Richard Gaynor, Edward S Kim
Purpose Broadening trial eligibility to improve accrual and access and to better reflect intended-to-treat populations has been recognized as a priority. Historically, patients with brain metastases have been understudied, because of restrictive eligibility across all phases of clinical trials. Methods In 2016, after a literature search and series of teleconferences, a multistakeholder workshop was convened. Our working group focused on developing consensus recommendations regarding the inclusion of patients with brain metastases in clinical trials, as part of a broader effort that encompassed minimum age, HIV status, and organ dysfunction...
October 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28967951/impact-of-2013-american-society-of-clinical-oncology-college-of-american-pathologists-guidelines-on-her2-fluorescent-in-situ-hybridization-testing-in-breast-cancers-experience-from-a-national-reference-laboratory
#15
H Evin Gulbahce
Objectives: We compared the impact of 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on human epidermal growth factor receptor 2 (HER2) fluorescence in situ hybridization (FISH) testing results on breast cancers. Methods: HER2 FISH testing performed between May 2015 and April 2016 following 2013 ASCO/CAP guidelines was included. HER2 to control probe ratios, mean HER2, and control probe copy numbers were used to reassign HER2 status using 2007 ASCO/CAP and US Food and Drug Administration (FDA) guidelines...
October 1, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28964588/precision-oncology-and-genomically-guided-radiation-therapy-a-report-from-the-american-society-for-radiation-oncology-american-association-of-physicists-in-medicine-national-cancer-institute-precision-medicine-conference
#16
William A Hall, Carmen Bergom, Reid F Thompson, Andrew M Baschnagel, Srinivasan Vijayakumar, Henning Willers, X Allen Li, Christopher J Schultz, George D Wilson, Catharine M L West, Jacek Capala, C Norman Coleman, Javier F Torres-Roca, Joanne Weidhaas, Felix Y Feng
PURPOSE: To summarize important talking points from a 2016 symposium focusing on real-world challenges to advancing precision medicine in radiation oncology, and to help radiation oncologists navigate the practical challenges of precision, radiation oncology. METHODS AND MATERIALS: The American Society for Radiation Oncology, American Association of Physicists in Medicine, and National Cancer Institute cosponsored a meeting on precision medicine in radiation oncology...
June 9, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28960111/evaluating-molecular-biomarkers-for-the-early-detection-of-lung-cancer-when-is-a-biomarker-ready-for-clinical-use-an-official-american-thoracic-society-policy-statement
#17
Peter J Mazzone, Catherine Rufatto Sears, Doug A Arenberg, Mina Gaga, Michael K Gould, Pierre P Massion, Vish S Nair, Charles A Powell, Gerard A Silvestri, Anil Vachani, Renda Soylemez Wiener
BACKGROUND: Molecular biomarkers have the potential to improve the current state of early lung cancer detection. The goal of this project was to develop a policy statement that provides guidance about the level of evidence required to determine that a molecular biomarker, used to support early lung cancer detection, is appropriate for clinical use. METHODS: An ad hoc project steering committee was formed, to include individuals with expertise in the early detection of lung cancer and molecular biomarker development, from inside and outside of the Assembly on Thoracic Oncology...
October 1, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28949948/highlights-in-breast-cancer-from-the-2017-american-society-of-clinical-oncology-annual-meeting
#18
Hope S Rugo
No abstract text is available yet for this article.
August 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28949939/highlights-in-kidney-cancer-from-the-2017-american-society-of-clinical-oncology-annual-meeting
#19
(no author information available yet)
No abstract text is available yet for this article.
September 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28942886/who-treats-lung-cancer-results-from-a-global-survey
#20
Takefumi Komiya, Christine B Mackay, Prabhakar Chalise
BACKGROUND: In most Western nations, the medical oncologist plays a significant role in the administration of systemic therapy for lung cancer. In Japan however, treatment for lung cancer has historically been provided by pulmonologists and thoracic surgeons. A comparison of the management of advanced disease between Japan and other nations has not been described. METHODS: An online, self-administered, international survey was sent to 3907 active members of the American Society of Clinical Oncology...
September 2017: Respiratory Investigation
keyword
keyword
77718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"